Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05888207
Other study ID # D5084C00015
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 2, 2023
Est. completion date August 17, 2023

Study information

Verified date August 2023
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the effects of strong CYP1A2 (Cytochrome P450 1A2) inhibitor (fluvoxamine) on savolitinib exposure in healthy male subjects, performed at a single clinical unit.


Description:

This study will be a Phase I, open-label, fixed-sequence, 2-treatment period study. The study will consist of 2 periods. During period 1 of the study, each subject will receive a single oral dose of savolitinib following an overnight fast. A low-fat breakfast will be provided prior to dosing. There will be a minimum washout period of 10 days (14 days between two successive savolitinib doses) between period 1 and period 2. During period 2 of the study, subject will take oral doses of fluvoxamine alone from Days 1 to 4. There would be no dietary restrictions for fluvoxamine dosing. On Day 5, subjects will take a single oral dose of savolitinib and oral dose of fluvoxamine. On Day 6, subject will receive an oral dose of fluvoxamine alone. Each subject would be involved in the study for 9 weeks (including screening window).


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date August 17, 2023
Est. primary completion date August 17, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Healthy subjects with suitable veins for cannulation or repeated venipuncture. - Male subjects must use barrier contraception. - Have a BMI between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive. - Regular bowel movements. Exclusion Criteria: - History of any clinically significant disease or disorder, which in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. - History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. - Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational medicinal product (IMP). - Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, vital signs, 12 lead ECG and physical examination. - QTcF > 450 ms or QT > 500 ms or other ECG abnormality making interpretation more difficult, as judged by the investigator, or a history of additional risk factors for Torsades de Points, which in the opinion of the investigator may put the subject at risk. - Any positive result on screening for serum hepatitis B surface antigen OR anti-HBc antibody, indicative of active hepatitis B, hepatitis C antibody, or HIV antibody. - History of latent or chronic infections. - Known or suspected drug or alcohol abuse or positive drugs of abuse test. History of excessive alcohol assumption or chronic alcohol induced disease. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol. - Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 1 month (30 days) of Visit 2 (Day -1 of Period 1) or 5 half lives whichever longer in this study or participation in a method development study (no drug) 1 month prior to Visit 2. The period of exclusion begins 1 month after the final dose or 5 half-lives after the final dose or 1 month after the last visit, whichever is the longest. - History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity. - Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 6 months prior to screening. - Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies (which include but are not limited to: kava, ephedra [ma hung], ginko biloba, dehydroepiandrosterone, yohimbe, saw palmetto and ginseng), megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer (> 5 half-lives) if the medication has a long half-life. - Subject has clinical signs and symptoms consistent with COVID-19, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission unless confirmed by a negative SARS CoV-2 PCR test. - History of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated). - Excessive intake of caffeine-containing drinks or food. - Planned in-patient surgery, dental procedure, or hospitalization during the study. - Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug. - Received a seasonal flu vaccine (including H1N1, H1N5) 28 days prior to first dose of study drug.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Savolitinib
Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
Fluvoxamine
Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.

Locations

Country Name City State
United States Research Site Brooklyn Maryland

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca Parexel

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum observed plasma (peak) drug concentration (Cmax) for savolitinib To evaluate the effects of fluvoxamine on savolitinib Cmax in healthy male subjects after administration of a single oral dose. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Primary Area under plasma concentration time curve from zero to infinity (AUCinf) for savolitinib To evaluate the effects of fluvoxamine on savolitinib AUCinf in healthy male subjects after administration of a single oral dose. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) for savolitinib To evaluate the AUClast of savolitinib when administered alone or in combination with fluvoxamine. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary AUClast for metabolites M2 and M3 To evaluate the AUClast of savolitinib metabolites (M2 and M3) when savolitinib is administered alone or in combination with fluvoxamine. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Cmax for metabolites M2 and M3 To evaluate the Cmax of savolitinib metabolites (M2 and M3) when savolitinib is administered alone or in combination with fluvoxamine. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary AUCinf for metabolites M2 and M3 To evaluate the AUCinf of savolitinib metabolites (M2 and M3) when savolitinib is administered alone or in combination with fluvoxamine. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Ratio of metabolite Cmax to parent Cmax (MRCmax) To evaluate the MRCmax of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Ratio of metabolite AUCinf to parent AUCinf (MRAUCinf) To evaluate the MRAUCinf of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Ratio of metabolite AUClast to parent AUClast (MRAUClast) To evaluate the MRAUClast of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Time to reach peak or maximum observed concentration or response following drug administration (tmax) for savolitinib and metabolites (M2 and M3) To evaluate the tmax of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Half life associated with terminal slope (?z) of a semi logarithmic concentration time curve (t1/2?z) for savolitinib and metabolites (M2 and M3) To evaluate the t1/2?z of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (?z) for savolitinib and metabolites (M2 and M3) To evaluate the ?z of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Number of data points used for ?z determination (?zN) for savolitinib and metabolites (M2 and M3) To evaluate the ?zN of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Apparent total body clearance of drug from plasma after extravascular administration (CL/F) for savolitinib To evaluate the CL/F of savolitinib when savolitinib is administered alone. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F) for savolitinib To evaluate the Vz/F of savolitinib when savolitinib is administered alone. Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
Secondary Number of subjects with adverse events (AEs) To assess additional safety and tolerability of savolitnib. From screening (Day -28 to Day -2) to follow up visit (approximately 9 weeks)
See also
  Status Clinical Trial Phase
Completed NCT05621447 - A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects Phase 1
Completed NCT02901366 - Mass Balance Study of FYU-981 Phase 2
Not yet recruiting NCT01928563 - Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine Phase 1
Completed NCT05559554 - A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects Phase 1
Completed NCT04512872 - A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects Phase 1
Active, not recruiting NCT06111196 - Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects Phase 1
Completed NCT03317652 - Effect of Sodium Nitroprusside on Cerebral Blood Flow N/A
Completed NCT04655872 - Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects Phase 1
Active, not recruiting NCT02609711 - Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects Phase 1
Withdrawn NCT02560363 - A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects Phase 1
Completed NCT01261260 - Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers Phase 1
Completed NCT05072028 - Mass Balance and Biotransformation Study of [14C]DBPR108 in Human Phase 1
Completed NCT05446233 - ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects Phase 1
Completed NCT05275010 - A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System Phase 1
Completed NCT04839744 - A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects Phase 1
Completed NCT05792917 - Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers Phase 1
Completed NCT03576651 - A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers Phase 1
Completed NCT04825431 - Mass Balance Study of [14C] TAS-205 in Healthy Volunteers Phase 1
Completed NCT01819779 - Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60) Phase 1
Completed NCT05126784 - AVT03 With Prolia in Healthy Male Subjects Phase 1